Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis

@article{Jun2010EffectsOF,
  title={Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis},
  author={Min Jun and Celine Foote and Ji-cheng Lv and Bruce Neal and Anushka Patel and Stephen J. Nicholls and Diederick E. Grobbee and Alan Cass and John Chalmers and Vlado Perkovic},
  journal={The Lancet},
  year={2010},
  volume={375},
  pages={1875-1884}
}
BACKGROUND Several clinical trials have reported inconsistent findings for the effect of fibrates on cardiovascular risk. We undertook a systematic review and meta-analysis to investigate the effects of fibrates on major clinical outcomes. METHODS We systematically searched Medline, Embase, and the Cochrane Library for trials published between 1950 and March, 2010. We included prospective randomised controlled trials assessing the effects of fibrates on cardiovascular outcomes compared with… Expand
Omega 3 Fatty Acids and Cardiovascular Outcomes: Systematic Review and Meta-Analysis
TLDR
&ohgr;-3 FA may protect against vascular disease, but the evidence is not clear-cut, and any benefits are almost certainly not as great as previously believed. Expand
Analysis of the Cochrane Review: Fibrates for secondary prevention of cardiovascular disease and stroke.
  • G. Pires da Rosa, D. Libânio, Luís Filipe Azevedo
  • Medicine
  • Revista portuguesa de cardiologia : orgao oficial da Sociedade Portuguesa de Cardiologia = Portuguese journal of cardiology : an official journal of the Portuguese Society of Cardiology
  • 2017
TLDR
Evidence is insufficient to support the routine prescription of fibrates in this setting, but this evidence should be taken into account when deciding on lipid-modifying therapy in dyslipidemic patients with a history of cardiovascular disease. Expand
Analysis of the Cochrane Review: Fibrates for secondary prevention of cardiovascular disease and stroke.
TLDR
Evidence is insufficient to support the routine prescription of fibrates in this setting, but this evidence should be taken into account when deciding on lipid-modifying therapy in dyslipidemic patients with a history of cardiovascular disease. Expand
Use of Fibrates and Cancer Risk: A Systematic Review and Meta-Analysis of 17 Long-Term Randomized Placebo-Controlled Trials
TLDR
The findings demonstrate that fibrates have a neutral effect on cancer outcomes, however, it is important to continue monitoring their long-term safety profiles. Expand
Effects of fibrates in kidney disease: a systematic review and meta-analysis.
TLDR
It is suggested that fibrates have a place in reducing cardiovascular risk in people with mild-to-moderate CKD and reduce albuminuria and reversibly increase serum creatinine but the effects on major kidney outcomes remain unknown. Expand
Comparative efficacy and safety of statin and fibrate monotherapy: A systematic review and meta-analysis of head-to-head randomized controlled trials.
TLDR
The eligible randomized trials of statins versus fibrates were designed to assess short-term lipid outcomes, making it difficult to have certainty about the direct comparative effect on cardiovascular outcomes and mortality, and with the exception of myalgia, use of a statin appeared to have a lower incidence of adverse effects compared toUse of a fibrate. Expand
Fibrates in primary prevention of cardiovascular disease. Comments on the results of a systematic review of the Cochrane Collaboration.
TLDR
Evidence of a protective effect of the fibrates compared with placebo is shown as regards a reduction 16% of a compound objective of death due to cardiovascular disease, non-fatal myocardial infarction, or non- fatal cerebrovascular accident. Expand
Efficacy of fibrates for cardiovascular risk reduction in persons with atherogenic dyslipidemia: a meta-analysis.
TLDR
Fibrate treatment directed at markers of atherogenic dyslipidemia substantially reduce subsequent vascular event risk, and may be particularly beneficial in patients with guideline-endorsed indications for therapy. Expand
fficacy of fibrates for cardiovascular risk reduction in persons with atherogenic yslipidemia : A meta-analysis
Background: Recent data suggest that non-targeted treatment with fibrates modestly reduces the risk of incident cardiovascular events. However the effect of fibrate treatment may be particularlyExpand
The effect of fibrate–statin combination therapy on cardiovascular events: a retrospective cohort analysis
TLDR
Fibrate–statin therapy in a population with mixed dyslipidaemia resulted in an improved lipid profile with few side-effects, and decreases in TG allied with modest decrease in cholesterol and an increase in HDL-C, were associated with better prognosis. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 60 REFERENCES
Improving outcomes through statin therapy - a review of ongoing trials
TLDR
The results of these trials will provide important information on how to maximise the therapeutic benefits of statin therapy in a broader range of patients at risk for cardiovascular morbidity and mortality. Expand
Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins
TLDR
Statin therapy can safely reduce the 5-year incidence of major coronary events, coronary revascularisation, and stroke by about one fifth per mmol/L reduction in LDL cholesterol, largely irrespective of the initial lipid profile or other presenting characteristics. Expand
Effects of combination lipid therapy in type 2 diabetes mellitus.
TLDR
The routine use of combination therapy with fenofibrate and simvastatin to reduce cardiovascular risk in the majority of high-risk patients with type 2 diabetes does not support the routine use. Expand
Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds: a meta-analysis of randomized controlled trials.
TLDR
Fibrates reduce major coronary events and increase HDL-C levels without significant toxicity, and niacin has a more potent effect on HDL- C levels, whereas data on cardiovascular event rate reduction are limited. Expand
Bezafibrate in men with lower extremity arterial disease: randomised controlled trial
TLDR
Bezafibrate has no effect on the incidence of coronary heart disease and of stroke combined but may reduce the incidenceof non-fatal coronary events, particularly in those aged <65 years at entry, in whom all coronary events may also be reduced. Expand
Bezafibrate following acute myocardial infarction: important findings from the bezafibrate coronary atherosclerosis intervention trial
TLDR
By correcting the underlying dyslipidaemia and the haemostatic imbalance, bezafibrate is able to slow the progression of coronary atherosclerosis in a group of young post-myocardial infarction patients. Expand
Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial
TLDR
Fenofibrate did not significantly reduce the risk of the primary outcome of coronary events, but it did reduce total cardiovascular events, mainly due to fewer non-fatal myocardial infarctions and revascularisations. Expand
Rosuvastatin and cardiovascular events in patients undergoing hemodialysis.
TLDR
In patients undergoing hemodialysis, the initiation of treatment with rosuvastatin lowered the LDL cholesterol level but had no significant effect on the composite primary end point of death from cardiovascular causes, nonf fatal myocardial infarction, or nonfatal stroke. Expand
Effects of Fenofibrate Treatment on Cardiovascular Disease Risk in 9,795 Individuals With Type 2 Diabetes and Various Components of the Metabolic Syndrome
TLDR
Metabolic syndrome components identify higher CVD risk in individuals with type 2 diabetes, so the absolute benefits of fenofibrate are likely to be greater when metabolic syndrome features are present. Expand
Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study
TLDR
Treatment with fenofibrate reduces the angiographic progression of coronary-artery disease in type 2 diabetes, even those previously judged not to need treatment, according to a computer-assisted quantitative approach. Expand
...
1
2
3
4
5
...